EP0861238A4 - Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique - Google Patents

Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique

Info

Publication number
EP0861238A4
EP0861238A4 EP96937836A EP96937836A EP0861238A4 EP 0861238 A4 EP0861238 A4 EP 0861238A4 EP 96937836 A EP96937836 A EP 96937836A EP 96937836 A EP96937836 A EP 96937836A EP 0861238 A4 EP0861238 A4 EP 0861238A4
Authority
EP
European Patent Office
Prior art keywords
heteroazepine
hexahydro
imino
inhibitors
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96937836A
Other languages
German (de)
English (en)
Other versions
EP0861238A1 (fr
Inventor
Charles G Caldwell
William K Hagmann
Malcolm Maccoss
Shrenik K Shah
Kothandaraman Shankaran
Karla L Furman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605162.8A external-priority patent/GB9605162D0/en
Priority claimed from GBGB9605700.5A external-priority patent/GB9605700D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0861238A1 publication Critical patent/EP0861238A1/fr
Publication of EP0861238A4 publication Critical patent/EP0861238A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96937836A 1995-11-01 1996-10-28 Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique Withdrawn EP0861238A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US717295P 1995-11-01 1995-11-01
US7172P 1995-11-01
US901295P 1995-12-21 1995-12-21
US9012P 1995-12-21
GBGB9605162.8A GB9605162D0 (en) 1996-03-12 1996-03-12 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9605162 1996-03-12
GBGB9605700.5A GB9605700D0 (en) 1996-03-19 1996-03-19 Hexahydro-5-imino,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9605700 1996-03-19
PCT/US1996/017447 WO1997016430A1 (fr) 1995-11-01 1996-10-28 Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique

Publications (2)

Publication Number Publication Date
EP0861238A1 EP0861238A1 (fr) 1998-09-02
EP0861238A4 true EP0861238A4 (fr) 2000-03-01

Family

ID=27451425

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937836A Withdrawn EP0861238A4 (fr) 1995-11-01 1996-10-28 Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique

Country Status (5)

Country Link
EP (1) EP0861238A4 (fr)
JP (1) JP3188715B2 (fr)
AU (1) AU700078B2 (fr)
CA (1) CA2234641A1 (fr)
WO (1) WO1997016430A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100342275B1 (ko) * 1993-10-21 2002-12-05 지.디. 썰 엘엘씨 산화질소신타제저해제로서유용한아미디노유도체
JPH11504319A (ja) * 1995-04-20 1999-04-20 ジー．ディー．サール アンド カンパニー 酸化窒素シンターゼインヒビターとして有用な環状アミジノ薬剤
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
AU4821799A (en) 1998-06-10 1999-12-30 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
SE9901530D0 (sv) * 1999-04-28 1999-04-28 Astra Pharma Prod Novel compounds
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
EP2085399A1 (fr) 2008-01-29 2009-08-05 Sanofi-Aventis Dérivés d'arylamide oxazépinopyrimidone substitués
EP2085400A1 (fr) 2008-01-29 2009-08-05 Sanofi-Aventis Dérivés d'hétéroarylamide oxazépinopyrimidone substitués
EP2090578A1 (fr) 2008-01-29 2009-08-19 Sanofi-Aventis Dérivés d'arylamide diazépinopyrimidone substitués pour le traitement des maladies neurodégénératives causées par une activité anormale de GSK3-beta
EP2090579A1 (fr) 2008-01-29 2009-08-19 Sanofi-Aventis Dérivés d'hétéroarylamide diazépinopyrimidone substitués
EP2138494A1 (fr) 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués d'alkyl pyrimidin-4-one
EP2138495A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés substitués de pyrimido[2,1-a]isoquinolin-4-one
EP2138493A1 (fr) 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués de pyrimidone
EP2138485A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés substitués de N-oxyde pyrazine
EP2138492A1 (fr) 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués de pyrimidin-4-one
EP2138498A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés tricycliques substitués contre les maladies neurodégénératives
EP2138488A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés de 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-ones comme inhibiteurs de GSK3-beta utiles pour le traitement de maladies neurodégénératives
PT4065567T (pt) 2019-11-26 2024-11-08 Gilead Sciences Inc Processos e intermediários para a preparação de inibidores de mcl1
JP7659630B2 (ja) 2020-11-19 2025-04-09 ギリアード サイエンシーズ， インコーポレイテッド 大環状ｍｃｌ１阻害剤を調製するための方法及び中間体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
FR1508536A (fr) * 1966-01-17 1968-01-05 American Cyanamid Co Nouveau procédé pour la préparation des 11-tert-aminodibenz[b, f][1, 4]oxazépines et thiazépines
FR2292479A1 (fr) * 1974-11-26 1976-06-25 Lilly Industries Ltd Derives de benzodiazepine
EP0129692A2 (fr) * 1983-05-18 1985-01-02 Hoechst-Roussel Pharmaceuticals Incorporated Dérivés de dibenzodiazépine, procédé pour leur préparation et leur utilisation comme médicaments
WO1995011231A1 (fr) * 1993-10-21 1995-04-27 G. D. Searle & Co. Derives amidino utiles en tant qu'inhibiteurs de la synthase de l'oxyde nitrique
WO1996014844A1 (fr) * 1994-11-15 1996-05-23 Merck & Co., Inc. Analogues d'amidines cycliques utilises comme inhibiteurs de la monoxyde d'azote synthetase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT355025B (de) * 1974-11-29 1980-02-11 Sandoz Ag Verfahren zur herstellung neuer 5-amino-7- phenyl-2,3-dihydro-1h-1,4-diazepine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
FR1508536A (fr) * 1966-01-17 1968-01-05 American Cyanamid Co Nouveau procédé pour la préparation des 11-tert-aminodibenz[b, f][1, 4]oxazépines et thiazépines
FR2292479A1 (fr) * 1974-11-26 1976-06-25 Lilly Industries Ltd Derives de benzodiazepine
EP0129692A2 (fr) * 1983-05-18 1985-01-02 Hoechst-Roussel Pharmaceuticals Incorporated Dérivés de dibenzodiazépine, procédé pour leur préparation et leur utilisation comme médicaments
WO1995011231A1 (fr) * 1993-10-21 1995-04-27 G. D. Searle & Co. Derives amidino utiles en tant qu'inhibiteurs de la synthase de l'oxyde nitrique
WO1996014844A1 (fr) * 1994-11-15 1996-05-23 Merck & Co., Inc. Analogues d'amidines cycliques utilises comme inhibiteurs de la monoxyde d'azote synthetase

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A. BAUER ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, no. 9, 1973, WASHINGTON US, pages 1011 - 1014, XP002126762 *
AMBROGI V ET AL: "Studies on annulated 1,4-benzothiazines and 1,5-benzothiazepines. IX. Imidazo[2,1-d][1,5]benzothiazepines: synthesis and in vitro benzodiazepine receptor affinity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA,FR,EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, vol. 30, no. 5, pages 429-437, XP004040163, ISSN: 0223-5234 *
C. CORRAL ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 14, no. 6, 1977, PROVO US, pages 985 - 988, XP002126761 *
CHEMICAL ABSTRACTS, vol. 92, no. 17, 28 April 1980, Columbus, Ohio, US; abstract no. 146818, ARYA, VISHWA PRAKASH: "Heterocyclic compounds having hypoglycemic properties" XP002126763 *
CHEMICAL ABSTRACTS, vol. 94, no. 9, 2 March 1981, Columbus, Ohio, US; abstract no. 65731, ALESHINA, G. A. ET AL: "11-Substituted-5H-dibenzo-[b,e][1,4]-diazepines" XP002126764 *
D. KORAKAS ET AL., SYNTHESIS, vol. 2, 1994, pages 164 - 166, XP002126757 *
H.A. HAMMOUDA ET AL., EGYPT. J. CHEM., vol. 30, no. 3, 1987, pages 239 - 247, XP002126759 *
K. TAGAKI ET AL., SYNTHESIS, vol. 4, 1987, pages 379 - 381, XP002126760 *
R. CAUJOLLE ET AL., EUR. J. MED. CHEM., vol. 28, no. 1, 1993, pages 29 - 35, XP002126758 *
See also references of WO9716430A1 *

Also Published As

Publication number Publication date
AU700078B2 (en) 1998-12-17
JPH11501327A (ja) 1999-02-02
AU7528796A (en) 1997-05-22
CA2234641A1 (fr) 1997-05-09
JP3188715B2 (ja) 2001-07-16
EP0861238A1 (fr) 1998-09-02
WO1997016430A1 (fr) 1997-05-09

Similar Documents

Publication Publication Date Title
HUP9800634A3 (en) P-amidino-benzylamide derivatives as thrombin inhibitors, intermediates and use thereof
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
EP0828485A4 (fr) Utilisation de r-enantiomere de n-propargyl-1-aminoindane, de sels et de compositions de celui-ci
AU3262997A (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
IL138028A0 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
PL324527A1 (en) Cyclic inhibitors of gmp-specific phosphodisterase
NO305833B1 (no) Naftylforbindelser, mellomprodukter og anvendelse av forbindelsene
PL324992A1 (en) Novel derivatives of 2,3-dioxotetrahydoquinoxaline
NO953629D0 (no) 2,9-diamino- og 2-amino-8-karbamoyl-4-hydroksy-alkansyreamid-derivater
IL125859A0 (en) Pyrrolopyrrolone derivatives useful as inhibitors of neutrophil elastase
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
HUP9901984A3 (en) Naphthyl acetamides as spla2 inhibitors, use thereof and pharmaceutical compositions containing these compounds
ZA964753B (en) Inhibitors of Factor Xa.
IT1277904B1 (it) Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
NO960699L (no) Antimigren 1,2,5-tiadiazolderivater av indolylalkylpyridinyl- og -pyrimidinylpiperaziner
FI956015A7 (fi) 5-asyyli-1,4-dihydropyridiinien käyttö
ZA988162B (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
ZA968444B (en) Methods of inhibiting plasminogen activator inhibitor 1.
ATE177102T1 (de) Chromanderivate
FI956016L (fi) 1,2-silloitettujen 1,4-dihydropyridiinien käyttö lääkeaineina
PT796843E (pt) Derivados de 1,25-di-hidroxi-16,22,23-trisde-hidro-colecalciferol
FR2730364B1 (fr) Amplificateur programmable d'instrumentation
IL120343A0 (en) Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-YL)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
ITMI931785A1 (it) Valilamidi di 7alfa-amino-1, 1-dioxo-cefem

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000118

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20001130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020319